Drug and Therapeutics Bulletin 2001;39:65-68; doi:10.1136/dtb.2001.39965
Copyright © 2001 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Pioglitazone and {blacktriangledown}rosiglitazone for diabetes

Relevant BNF section: 6.1.2.3

&#9660Pioglitazone* (Actos - Takeda) and &#9660rosiglitazone* (Avandia - GlaxoSmithKline) belong to a new class of oral antidiabetic medicines (the glitazones or thiazolidinediones). Both are licensed in the UK for "oral combination treatment of type 2 diabetes mellitus in [narrowly defined groups of] patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea". They are not licensed for use as monotherapy, in combination with insulin, or as part of triple therapy with metformin or a sulphonylurea. What can pioglitazone and rosiglitazone offer in the management of patients with type 2 diabetes?




This article has been cited by other articles:


Home page
 DTBHome page
Glitazones in type 2 diabetes: an update
DTB, April 1, 2008; 46(4): 25 - 29.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2001 BMJ Publishing Group Ltd.